Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 29;4(5):e371.
doi: 10.1002/ski2.371. eCollection 2024 Oct.

Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab

Gennaro Marco Falco  1   2 , Giacomo Caldarola  1   2 , Alessandra D'Amore  1   2 , Lorenzo Maria Pinto  1   2 , Clara De Simone  1   2 , Ketty Peris  1   2
Affiliations

Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab

Gennaro Marco Falco et al. Skin Health Dis. .

Abstract

Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.

PubMed Disclaimer

Conflict of interest statement

G. Caldarola has received consulting fees, honoraria and support for attending meetings from Abbvie, Lilly, Janssen, UCB, Novartis and Leopharma; C. De Simone has received support for consulting fees, honoraria and support for attending meetings from Abbvie, Lilly, Janssen, UCB, Novartis, Leopharma, Sanofi and Almiral; K. Peris has received support for consulting fees and honoraria from Abbvie, Almirall, Biogen, Celgene, Janssen Galderma, Novartis, Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi and Sun Pharma. All other authors declare that they have no conflicts of interest relevant to this manuscript.

Figures

FIGURE 1
FIGURE 1
(a) Multiple psoriasis plaques in the groin. (b) Single eczematous patch localised on the left arm, appeared 1 month after starting bimekizumab. (c) Multiple eczematous lesions localised on the right leg, appeared 2 months after starting bimekizumab.
FIGURE 2
FIGURE 2
Histopathology of an eczematous lesion showing severe spongiosis with spongiotic vesicles and lymphocitic exocytosis.
See this image and copyright information in PMC

References

    1. Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52‐week, multicentre, double‐blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. 10.1016/s0140-6736(21)00125-2 - DOI - PubMed
    1. Al‐Janabi A, Foulkes AC, Mason K, Smith C, Griffiths C, Warren R. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1440–1448. 10.1111/jdv.16246 - DOI - PubMed
    1. Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D’Adamio S, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL‐17 treatment: a case series and review of the literature. Expet Opin Biol Ther. 2020;20(6):665–672. 10.1080/14712598.2020.1727439 - DOI - PubMed
    1. Chicharro P, Rodríguez‐Jiménez P, De la Fuente H, Fraga‐Fernández J, Cibrian D, Sánchez‐Madrid F, et al. Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti‐IL‐17 therapy. J Allergy Clin Immunol Pract. 2020;8(10):3619–3621.e1. 10.1016/j.jaip.2020.06.064 - DOI - PubMed
    1. Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, et al. Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role? Clin Exp Dermatol. 2022;47(5):918–925. 10.1111/ced.15052 - DOI - PubMed

LinkOut - more resources